Table 3 The clinical trials of the oncolytic virus in combination with immune checkpoint inhibitors (ICIs)

From: Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies

Oncolytic virus	Agents	Indication	Combination	Clinical trial ID	phase
Vaccinia Virus	Pexa-Vec	Renal Cell Carcinoma	REGN2810 (Anti-PD-1)	NCT03294083	I
	Pexa-Vec	Solid Tumor	Ipilimumab	NCT02977156	I
	ChAdOx1-MVA 5T4 vaccine	Prostate Cancer	Nivolumab	NCT03815942	I,II
	p53MVA Vaccine	Solid tumor	Pembrolizumab	NCT02432963	I
	Pexa-Vec	Colorectal Cancer	Tremelimumab, Durvalumab	NCT03206073	I,II
	p53MVA Vaccine	Ovarian Cancer	Pembrolizumab	NCT03113487	II
	PROSTVAC	Prostate Cancer	Nivolumab, Ipilimumab	NCT03532217	I
	p53MVA Vaccine	Solid tumor	Pembrolizumab	NCT02432963	I
	TG4010	Non-Small Cell Lung Cancer	Nivolumab	NCT02823990, NCT03353675	II
Herpes simplex virus	OH2	Solid Tumor Melanoma	Keytruda	NCT04386967	I,II
	ONCR-177	Solid Tumor	Pembrolizumab	NCT04348916	I
	OrienX010	Melanoma	JS001	NCT04206358	I
	OH2	Solid Tumor	HX008	NCT03866525	I,II
	OrienX010	Melanoma	Treprizumab	NCT04197882	I
	RP1	Solid Tumor	Nivolumab	NCT03767348	I,II
	ADV/HSV-tk	Non-small Cell Lung Cancer Triple-negative Breast Cancer	Pembrolizumab	NCT03004183	II
	RP2	Solid Tumor	Nivolumab	NCT04336241	II
	Talimogene Laherparepvec	Melanoma	Pembrolizumab	NCT02965716	II
	HF10	Melanoma	Nivolumab	NCT03259425	I,II
	Talimogene laherparepvec	Hepatocellular carcinoma	Pembrolizumab	NCT02509507	I
	Talimogene Laherparepvec	Sarcoma	Pembrolizumab	NCT03069378	II
	Talimogene Laherparepvec	squamous cell carcinoma of the head and neck	Pembrolizumab	NCT02626000	II
	Talimogene Laherparepvec	Melanoma	Pembrolizumab	NCT02263508	III
	Talimogene Laherparepvec	Breast Cancer	Ipilimumab Nivolumab	NCT04185311	I
Adenovirus	ONCOS-102	Melanoma	Pembrolizumab	NCT03003676	I
	DNX-2401	Brain Cancer	Pembrolizumab	NCT02798406	II
	VCN-01	Head and Neck Neoplasms	Durvalumab	NCT03799744	I
	Ad-MAGEA3	Non-Small Cell Lung Cancer	Pembrolizumab	NCT02879760	I,II
	ONCOS-102	Colorectal Cancer	Durvalumab	NCT02963831	I,II
	Enadenotucirev	Colorectal Cancer	Nivolumab	NCT02636036	I
	OBP-301	Solid tumor	Pembrolizumab	NCT03172819	I
	ONCOS-102	Melanoma	Pembrolizumab	NCT03003676	I
Measles virus	TMV-018	Gastrointestinal Cancer	Anti-PD-1 checkpoint inhibitor	NCT04195373	I
Reovirus	Pelareorep	Breast Cancer	Retifanlimab	NCT04445844	II
Coxsackievirus	CVA21	Non-Small Cell Lung Cancer	Pembrolizumab	NCT02824965	I

Back to article page

Table 3 The clinical trials of the oncolytic virus in combination with immune checkpoint inhibitors (ICIs)

Search

Quick links